title: Are Allogeneic Blood Transfusions Associated With Decreased Survival After Surgery for Long-bone Metastatic Fractures?
abstract: BACKGROUND
  Previous studies have shown that perioperative blood transfusion increases cancer recurrence and decreases patient survival after resection of primary malignancies. The question arises whether this association also exists in patients with already disseminated disease undergoing surgery for metastatic long-bone fractures.
  
  
  OBJECTIVE
  We sought to determine whether perioperative allogeneic blood transfusion is associated with decreased survival after operative treatment of long-bone metastatic fractures after accounting for clinical, laboratory, and treatment factors. Secondarily, we aimed to identify potential factors that are associated with decreased survival.
  
  
  METHODS
  We included 789 patients in our retrospective study who underwent surgery at two institutions for a pathologic or impending metastatic long-bone fracture. We used multivariable Cox proportional hazards regression model analysis to assess the relationship of perioperative allogeneic blood transfusion with survival, and accounted for patient age, sex, comorbidities, BMI, tumor type, fracture type and location, presence of other bone and visceral metastases, previous radiotherapy and systemic therapy, preoperative embolization, preoperative hemoglobin level, treatment type, anesthesia time, blood loss, duration of hospital admission, year of surgery, and hospital.
  
  
  RESULTS
  Considering transfusion as an "exposure," and comparing patients who received transfusions with those who did not, we found that blood transfusion was not associated with decreased survival after accounting for all explanatory variables (hazard ratio [HR] 1.06; 95% CI, 0.87-1.30; p = 0.57). Evaluating transfusion in terms of dose-response, we found that patients who received more transfusions had lower survival compared with those who had fewer transfusions after accounting for all explanatory variables (HR per unit of blood transfused, 1.07; 95% CI, 1.02-1.12; p = 0.005). We found that age (HR, 1.02; 95% CI, 1.01-1.02; p < 0.001), comorbidity status (HR, 1.06; 95% CI, 1.01-1.10; p = 0.014), duration of hospital stay (HR, 1.02; 95% CI 1.00-1.03; p = 0.021), tumor type (HR, 1.71; 95% CI, 1.44-2.03; p < 0.001), and visceral metastases (HR, 1.59; 95% CI, 1.34-1.88; p < 0.001) were independently associated with survival.
  
  
  CONCLUSIONS
  We found that exposure to perioperative allogeneic blood transfusion does not decrease survival, with the numbers available. However, our sample size might have been insufficient to reveal a small but potentially relevant effect. Our results do suggest a dose-response relationship; patients who received more transfusions had lower survival compared with those with fewer transfusions. Risk of death increased by 7% per unit of blood transfused.
  
  
  METHODS
  Level III, prognostic study.
authors: Department of Orthopaedic Surgery, Orthopaedic Oncology Service, Massachusetts General Hospital - Harvard Medical School, Room 3.946, Yawkey Building, 55 Fruit Street, Boston, MA, 02114, USA, steinjanssen@gmail.com.
authors: Stein J
authors: SJ
authors: Janssen
authors: Yvonne
authors: Y
authors: Braun
authors: John E
authors: JE
authors: Ready
authors: Kevin A
authors: KA
authors: Raskin
authors: Marco L
authors: ML
authors: Ferrone
authors: Francis J
authors: FJ
authors: Hornicek
authors: Joseph H
authors: JH
authors: Schwab
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary* / Q000601:surgery*; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000401:mortality* / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D065227:Transfusion Reaction
references: Nat Rev Cancer. 2002 Aug;2(8):584-93
references: 12154351
references: J Bone Joint Surg Br. 2005 May;87(5):698-703
references: 15855375
references: Acta Orthop Scand. 1995 Apr;66(2):143-6
references: 7740944
references: Lancet. 1993 Nov 27;342(8883):1328-33
references: 7901637
references: Eur Urol. 2013 May;63(5):947-52
references: 23273681
references: Transplant Proc. 1973 Mar;5(1):253-9
references: 4572098
references: Arch Gynecol Obstet. 2013 May;287(5):1009-16
references: 23229580
references: Am J Epidemiol. 2011 Mar 15;173(6):676-82
references: 21330339
references: Lancet. 1981 Aug 15;2(8242):363
references: 6115133
references: World J Surg. 2008 Jun;32(6):1130-7
references: 18340483
references: J Clin Oncol. 1988 Aug;6(8):1348-54
references: 3045268
references: J Clin Oncol. 2005 Sep 1;23(25):6072-82
references: 16135474
references: Best Pract Res Clin Anaesthesiol. 2008 Sep;22(3):503-17
references: 18831300
references: J Chronic Dis. 1987;40(5):373-83
references: 3558716
references: Clin Orthop Relat Res. 2014 May;472(5):1638-44
references: 24276857
references: J Bone Joint Surg Br. 2001 May;83(4):471-81
references: 11380113
references: Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S230-44
references: 14600615
references: Eur Spine J. 2014 Aug;23(8):1791-6
references: 24866254
references: Instr Course Lect. 2014;63:431-41
references: 24720328
references: Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s
references: 17062708
references: Med Care. 2002 Aug;40(8):675-85
references: 12187181
references: J Bone Joint Surg Am. 2009 Jun;91(6):1503-16
references: 19487532
references: J Clin Epidemiol. 1992 Jun;45(6):613-9
references: 1607900
references: Am J Cancer Res. 2013 Nov 01;3(5):518-22
references: 24224129
references: Eur Urol. 2013 May;63(5):839-45
references: 23332883
references: Cochrane Database Syst Rev. 2006;(1):CD005033
references: 16437512